Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
Traded Sep 14, 2026 · Filed Sep 15, 2026
A Humacyte director paid $5.6K out of pocket for Humacyte shares. Shares held went up 25% with this purchase.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell.
open market purchase
Code P — open-market or private purchase
~$5,620
Shares × reported transaction price
<$25K
+25.0%
Purchase shares ÷ estimated pre-transaction holdings, from the filing
First purchase in 1 month
Confirmed open-market purchases by the same insider in the available history
No
Compared with 2 earlier confirmed purchases
No other insider purchases within 30 days
Distinct insiders at the same issuer with confirmed open-market purchases
33 days after results of Aug 12, 2026, 57 days before results of Nov 10, 2026
Results dates are the company's own 8-K (Item 2.02). Many companies only let insiders trade in a window after results
Closed at $0.561 on Sep 14, 2026, within 2% of its 52-week low, after a 14% drop over the previous 30 trading days
52-week range $0.55 (Aug 13, 2026) to $2.48 (Oct 6, 2025), 1% of the way up, from 251 adjusted closes. 30 trading days earlier: $0.6534 on Jul 31, 2026. Describes the past only, not a forecast
None found in footnotes
Only flagged when a footnote says so; never inferred
Traded 8 days before HUMA filed an 8-K: changed a top executive or board member, and shared information with investors (Sep 22, 2026)
Compared with every open-market purchase and sale of this company in SEC filings since 2006. A fact about the record, not a signal to trade
| After | Stock | S&P 500 | Difference |
|---|---|---|---|
| 7 days | −0.8% | +1.8% | −2.6% |
| 30 days | −24.7% | +1.2% | −26.0% |
Past results only. Not a forecast.
Insider filing
Traded Oct 6 · filed 1 day later
Compensation award — excluded from discretionary-purchase analysis.
Insider filing
Traded Oct 6 · filed 1 day later
Compensation award — excluded from discretionary-purchase analysis.
Insider buying
Traded Aug 20 · filed 1 day later
A Humacyte director paid $6.9K out of pocket for Humacyte shares. Shares held went up 33% with this purchase.
Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.
Keith Anthony Jones, Director's past purchases, 30 days after disclosure: 3 buys, median −15.1 pts vs S&P 500, beat it 0 of 3 times. Past results, not a forecast.